The Secrets of Acinetobacter Secretion

Trends in Microbiology

Volumn 25, Issue 7, 2017, Pages 532-545

  Weber, Brent S ^a,b   Kinsella, Rachel L ^a,b   Harding, Christian M ^a   Feldman, Mario F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Acinetobacter; Autotransporters; Outer membrane vesicle; Secretion systems; T2SS; T6SS

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; OUTER MEMBRANE PROTEIN;

ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; BACTERIAL CELL; BACTERIAL SECRETION SYSTEM; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CARBOXY TERMINAL SEQUENCE; CELL VACUOLE; HUMAN; MICROBIAL ACTIVITY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; TYPE II SECRETION SYSTEM; TYPE VI SECRETION SYSTEM; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PATHOPHYSIOLOGY; TYPE V SECRETION SYSTEM;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; BACTERIAL OUTER MEMBRANE PROTEINS; TYPE II SECRETION SYSTEMS; TYPE V SECRETION SYSTEMS; TYPE VI SECRETION SYSTEMS;

EID: 85012906014     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2017.01.005     Document Type: Review

References (102)

1. Boucher, H.W., Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48 (2009), 1–12.
2. Infectious Diseases Society of America, Combating antimicrobial resistance: policy recommendations to save lives. Clin. Infect. Dis. 52:Suppl. 5 (2011), S397–S428.
3. Fowler, T., The risk/benefit of predicting a post-antibiotic era: is the alarm working?. Ann N. Y. Acad. Sci. 1323 (2014), 1–10.
4. Spellberg, B., The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46 (2008), 155–164.
5. Talbot, G.H., Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42 (2006), 657–668.
6. Valencia, R., Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital. Infect. Control Hosp. Epidemiol. 30 (2009), 257–263.
7. Falagas, M.E., Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int. J. Antimicrob. Agents 32 (2008), 450–454.
8. Sievert, D.M., Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect. Control Hosp. Epidemiol. 34 (2013), 1–14.
9. Peleg, A.Y., Hooper, D.C., Hospital-acquired infections due to Gram-negative bacteria. N. Engl. J. Med. 362 (2010), 1804–18013.
10. Gaynes, R., Edwards, J.R., Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect. Dis. 41 (2005), 848–854.
11. Grandi, G., Bacterial surface proteins and vaccines. F1000 Biol. Rep., 2, 2010, 36.
12. Nivaskumar, M., Francetic, O., Type II secretion system: a magic beanstalk or a protein escalator. Biochim. Biophys. Acta 1843 (2014), 1568–1577.
13. Sandkvist, M., Type II secretion and pathogenesis. Infect. Immun. 69 (2001), 3523–3535.
14. DebRoy, S., Legionella pneumophila type II secretome reveals unique exoproteins and a chitinase that promotes bacterial persistence in the lung. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 19146–19151.
15. McCoy-Simandle, K., et al. Legionella pneumophila type II secretion dampens the cytokine response of infected macrophages and epithelia. Infect. Immun. 79 (2011), 1984–1997.
16. Sandkvist, M., et al. A protein required for secretion of cholera toxin through the outer membrane of Vibrio cholerae. Gene 123 (1993), 81–86.
17. Sikora, A.E., Proteomic analysis of the Vibrio cholerae type II secretome reveals new proteins, including three related serine proteases. J. Biol. Chem. 286 (2011), 16555–16566.
18. Ho, T.D., Type 2 secretion promotes enterohemorrhagic Escherichia coli adherence and intestinal colonization. Infect. Immun. 76 (2008), 1858–1865.
19. Baldi, D.L., The type II secretion system and its ubiquitous lipoprotein substrate, SslE, are required for biofilm formation and virulence of enteropathogenic Escherichia coli. Infect. Immun. 80 (2012), 2042–2052.
20. Jyot, J., Type II secretion system of Pseudomonas aeruginosa: in vivo evidence of a significant role in death due to lung infection. J. Infect. Dis. 203 (2011), 1369–1377.
21. Eijkelkamp, B.A., Comparative analysis of surface-exposed virulence factors of Acinetobacter baumannii. BMC Genomics, 15, 2014, 1020.
22. Johnson, T.L., Acinetobacter baumannii is dependent on the type ii secretion system and its substrate lipa for lipid utilization and in vivo fitness. J. Bacteriol. 198 (2016), 711–719.
23. Douzi, B., et al. On the path to uncover the bacterial type II secretion system. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367 (2012), 1059–1072.
24. Possot, O.M., Multiple interactions between pullulanase secreton components involved in stabilization and cytoplasmic membrane association of PulE. J. Bacteriol. 182 (2000), 2142–2152.
25. Wang, N., et al. Genome-wide identification of Acinetobacter baumannii genes necessary for persistence in the lung. mBio 5 (2014), 01163–1214.
26. Harding, C.M., Medically relevant Acinetobacter species require a type ii secretion system and specific membrane-associated chaperones for the export of multiple substrates and full virulence. PLoS Pathog., 12, 2016, e1005391.
27. Tilley, D., CpaA a novel protease from Acinetobacter baumannii clinical isolates deregulates blood coagulation. FEMS Microbiol. Lett. 356 (2014), 53–61.
28. Zheng, X., Probing the molecular determinant of the lipase-specific foldase Lif26 for the interaction with its cognate Lip26. Int. J. Biol. Macromol. 53 (2013), 54–61.
29. Page, A.L., Parsot, C., Chaperones of the type III secretion pathway: jacks of all trades. Mol. Microbiol. 46 (2002), 1–11.
30. El Khattabi, M., Role of the lipase-specific foldase of Burkholderia glumae as a steric chaperone. J. Biol. Chem. 275 (2000), 26885–26891.
31. Chapon-Herve, V., Regulation of the xcp secretion pathway by multiple quorum-sensing modulons in Pseudomonas aeruginosa. Mol. Microbiol. 24 (1997), 1169–1178.
32. Lewenza, S., Quorum sensing in Burkholderia cepacia: identification of the LuxRI homologs CepRI. J. Bacteriol. 181 (1999), 748–756.
33. Zielke, R.A., The type II secretion pathway in Vibrio cholerae is characterized by growth phase-dependent expression of exoprotein genes and is positively regulated by sigmaE. Infect. Immun. 82 (2014), 2788–2801.
34. Jacobs, A.C., Characterization of the Acinetobacter baumannii growth phase-dependent and serum responsive transcriptomes. FEMS Immunol. Med. Microbiol. 64 (2012), 403–412.
35. Ruhe, Z.C., Bacterial contact-dependent growth inhibition. Trends Microbiol. 21 (2013), 230–237.
36. Russell, A.B., Type VI secretion system effectors: poisons with a purpose. Nat. Rev. Microbiol. 12 (2014), 137–148.
37. Pukatzki, S., Identification of a conserved bacterial protein secretion system in Vibrio cholerae using the Dictyostelium host model system. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 1528–1533.
38. Mougous, J.D., A virulence locus of Pseudomonas aeruginosa encodes a protein secretion apparatus. Science 312 (2006), 1526–1530.
39. Hood, R.D., A type VI secretion system of Pseudomonas aeruginosa targets a toxin to bacteria. Cell Host Microbe 7 (2010), 25–37.
40. Boyer, F., et al. Dissecting the bacterial type VI secretion system by a genome wide in silico analysis: what can be learned from available microbial genomic resources?. BMC Genomics, 10, 2009, 104.
41. Silverman, J.M., Structure and regulation of the type VI secretion system. Annu. Rev. Microbiol. 66 (2012), 453–472.
42. Basler, M., Type VI secretion requires a dynamic contractile phage tail-like structure. Nature 483 (2012), 182–186.
43. Russell, A.B., Type VI secretion delivers bacteriolytic effectors to target cells. Nature 475 (2011), 343–347.
44. Pukatzki, S., The type VI secretion system: translocation of effectors and effector-domains. Curr. Opin. Microbiol. 12 (2009), 11–17.
45. Pukatzki, S., Type VI secretion system translocates a phage tail spike-like protein into target cells where it cross-links actin. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 15508–15513.
46. Weber, B.S., Genetic dissection of the type vi secretion system in Acinetobacter and identification of a novel peptidoglycan hydrolase, TagX, required for its biogenesis. mBio, 7, 2016 e01253–16.
47. de Berardinis, V., A complete collection of single-gene deletion mutants of Acinetobacter baylyi ADP1. Mol. Systems Biol., 4, 2008, 174.
48. Zoued, A., Priming and polymerization of a bacterial contractile tail structure. Nature 531 (2016), 59–63.
49. Bonemann, G., Remodelling of VipA/VipB tubules by ClpV-mediated threading is crucial for type VI protein secretion. EMBO J. 28 (2009), 315–325.
50. Ruiz, F.M., Crystal structure of Hcp from Acinetobacter baumannii: a component of the type VI secretion system. PLoS One, 10, 2015, e0129691.
51. Brunet, Y.R., The type VI secretion TssEFGK-VgrG phage-like baseplate is recruited to the TssJLM membrane complex via multiple contacts and serves as assembly platform for tail tube/sheath polymerization. PLoS Genet., 11, 2015, e1005545.
52. Durand, E., Biogenesis and structure of a type VI secretion membrane core complex. Nature 523 (2015), 555–560.
53. Pietrosiuk, A., Molecular basis for the unique role of the AAA+ chaperone ClpV in type VI protein secretion. J. Biol. Chem. 286 (2011), 30010–30021.
54. Shneider, M.M., PAAR-repeat proteins sharpen and diversify the type VI secretion system spike. Nature 500 (2013), 350–353.
55. Felisberto-Rodrigues, C., Towards a structural comprehension of bacterial type VI secretion systems: characterization of the TssJ-TssM complex of an Escherichia coli pathovar. PLoS Pathog., 7, 2011, e1002386.
56. Aschtgen, M.S., SciN is an outer membrane lipoprotein required for type VI secretion in enteroaggregative Escherichia coli. J. Bacteriol., 190, 2008 7523–7231.
57. Aschtgen, M.S., Anchoring the type VI secretion system to the peptidoglycan: TssL, TagL, TagP. what else?. Virulence 1 (2010), 535–540.
58. Silverman, J.M., Separate inputs modulate phosphorylation-dependent and -independent type VI secretion activation. Mol. Microbiol. 82 (2011), 1277–1290.
59. Henry, R., Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-beta-1,6-N-acetylglucosamine. Antimicrob. Agents Chemother. 56 (2012), 59–69.
60. Weber, B.S., Genomic and functional analysis of the type VI secretion system in Acinetobacter. PLoS One, 8, 2013, e55142.
61. Carruthers, M.D., Acinetobacter baumannii utilizes a type VI secretion system for bacterial competition. PLoS One, 8, 2013, e59388.
62. Repizo, G.D., et al. Differential role of the T6SS in Acinetobacter baumannii virulence. PLoS One, 10, 2015, e0138265.
63. Weber, B.S., A multidrug resistance plasmid contains the molecular switch for type VI secretion in Acinetobacter baumannii. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 9442–9447.
64. Scheurwater, E.M., Burrows, L.L., Maintaining network security: how macromolecular structures cross the peptidoglycan layer. FEMS Microbiol. Lett. 318 (2011), 1–9.
65. Subashchandrabose, S., et al. Acinetobacter baumannii genes required for bacterial survival during bloodstream infection. mSphere 1 (2016), e00013–e00015.
66. Umland, T.C., et al. In vivo-validated essential genes identified in Acinetobacter baumannii by using human ascites overlap poorly with essential genes detected on laboratory media. mBio, 3, 2012 e00113–12.
67. Wright, M.S., et al. New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis. mBio, 5, 2014 e00963–13.
68. Eijkelkamp, B.A., H-NS plays a role in expression of Acinetobacter baumannii virulence features. Infect. Immun. 81 (2013), 2574–2583.
69. Bentancor, L.V., Identification of Ata, a multifunctional trimeric autotransporter of Acinetobacter baumannii. J. Bacteriol. 194 (2012), 3950–3960.
70. Weidensdorfer, M., Analysis of endothelial adherence of Bartonella henselae and Acinetobacter baumannii using a dynamic human ex vivo infection model. Infect. Immun. 84 (2016), 711–722.
71. Eijkelkamp, B.A., H-NS plays a role in expression of Acinetobacter baumannii virulence features. Infect. Immun. 81 (2013), 2574–2583.
72. Ishikawa, M., AtaA, a new member of the trimeric autotransporter adhesins from Acinetobacter sp. Tol 5 mediating high adhesiveness to various abiotic surfaces. PLoS One, 7, 2012, e48830.
73. Koiwai, K., Structural basis for toughness and flexibility in the C-terminal passenger domain of an Acinetobacter trimeric autotransporter adhesin. J. Biol. Chem. 291 (2016), 3705–3724.
74. Ishikawa, M., Discovery of a novel periplasmic protein that forms a complex with a trimeric autotransporter adhesin and peptidoglycan. Mol. Microbiol. 101 (2016), 394–410.
75. Elhenawy, W., et al. Preferential packing of acidic glycosidases and proteases into Bacteroides outer membrane vesicles. mBio 5 (2014), e00909–e00914.
76. Haurat, M.F., Selective sorting of cargo proteins into bacterial membrane vesicles. J. Biol. Chem. 286 (2011), 1269–1276.
77. Roier, S., A novel mechanism for the biogenesis of outer membrane vesicles in Gram-negative bacteria. Nat. Commun., 7, 2016, 10515.
78. Elhenawy, W., LPS Remodeling triggers formation of outer membrane vesicles in Salmonella. mBio, 7, 2016 e00940–16.
79. Ellis, T.N., Kuehn, M.J., Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol. Mol. Biol. Rev. 74 (2010), 81–94.
80. Nho, J.S., Acinetobacter nosocomialis secretes outer membrane vesicles that induce epithelial cell death and host inflammatory responses. Microb. Pathog. 81 (2015), 39–45.
81. Fulsundar, S., et al. Molecular characterization of outer membrane vesicles released from Acinetobacter radioresistens and their potential roles in pathogenesis. Microb. Pathog. 83–84 (2015), 12–22.
82. Fulsundar, S., Gene transfer potential of outer membrane vesicles of Acinetobacter baylyi and effects of stress on vesiculation. Appl. Environ. Microbiol. 80 (2014), 3469–3483.
83. Choi, C.H., Outer membrane protein 38 of Acinetobacter baumannii localizes to the mitochondria and induces apoptosis of epithelial cells. Cell. Microbiol. 7 (2005), 1127–1138.
84. Jin, J.S., Acinetobacter baumannii secretes cytotoxic outer membrane protein A via outer membrane vesicles. PLoS One, 6, 2011, e17027.
85. Kwon, S.O., et al. Proteome analysis of outer membrane vesicles from a clinical Acinetobacter baumannii isolate. FEMS Microbiol. Lett. 297 (2009), 150–156.
86. Koning, R.I., Cryo-electron tomography analysis of membrane vesicles from Acinetobacter baumannii ATCC19606T. Res. Microbiol. 164 (2013), 397–405.
87. Moon, D.C., Acinetobacter baumannii outer membrane protein A modulates the biogenesis of outer membrane vesicles. J. Microbiol. 50 (2012), 155–160.
88. Mendez, J.A., et al. Extracellular proteome of a highly invasive multidrug-resistant clinical strain of Acinetobacter baumannii. J. Proteome Res. 11 (2012), 5678–5694.
89. Li, Z.T., Outer membrane vesicles isolated from two clinical Acinetobacter baumannii strains exhibit different toxicity and proteome characteristics. Microb. Pathog. 81 (2015), 46–52.
90. Cerqueira, G.M., Peleg, A.Y., Insights into Acinetobacter baumannii pathogenicity. IUBMB Life 63 (2011), 1055–1060.
91. Jun, S.H., Acinetobacter baumannii outer membrane vesicles elicit a potent innate immune response via membrane proteins. PLoS One, 8, 2013, e71751.
92. Rumbo, C., et al. Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: a new mechanism of dissemination of carbapenem resistance genes in Acinetobacter baumannii. Antimicrob. Agents Chemother. 55 (2011), 3084–3090.
93. Liao, Y.T., Acinetobacter baumannii extracellular OXA-58 is primarily and selectively released via outer membrane vesicles after Sec-dependent periplasmic translocation. Antimicrob. Agents Chemother. 59 (2015), 7346–7354.
94. Liao, Y.T., et al. Sheltering effect and indirect pathogenesis of carbapenem-resistant Acinetobacter baumannii in polymicrobial infection. Antimicrob. Agents Chemother. 58 (2014), 3983–3990.
95. Price, N.L., Glycoengineered outer membrane vesicles: a novel platform for bacterial vaccines. Sci. Rep., 6, 2016, 24931.
96. McConnell, M.J., Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine 29 (2011), 5705–5710.
97. Huang, W., Immunization against multidrug-resistant Acinetobacter baumannii effectively protects mice in both pneumonia and sepsis models. PLoS One, 9, 2014, e100727.
98. King, L.B., Serine protease PKF of Acinetobacter baumannii results in serum resistance and suppression of biofilm formation. J. Infect. Dis. 207 (2013), 1128–1134.
99. Bahl, C.D., Signature motifs identify an Acinetobacter Cif virulence factor with epoxide hydrolase activity. J. Biol. Chem. 289 (2014), 7460–7469.
100. Jacobs, A.C., Inactivation of phospholipase D diminishes Acinetobacter baumannii pathogenesis. Infect. Immun. 78 (2010), 1952–1962.
101. Stahl, J., Acinetobacter baumannii virulence is mediated by the concerted action of three phospholipases D. PLoS One, 10, 2015, e0138360.
102. Camarena, L., et al. Molecular mechanisms of ethanol-induced pathogenesis revealed by RNA-sequencing. PLoS Pathog., 6, 2010, e1000834.